References—click links below:
  Recent Advances in the Systemic Treatment of CRC
  New Challenges for Symptom Management in CRC
  Maximizing the Interface Between Clinic and Home Care

 

Recent Advances in the Systemic Treatment of CRC
Catherine M. Handy, PhD, RN, AOCN

  1. American Cancer Society. Cancer facts & figures 2003. Available at: http://www.cancer.org/downloads/STT/CAFF2003PWSecured.pdf. Accessed May 9, 2003.
  2. MacDonald J. Adjuvant therapy of colon cancer. CA Cancer J Clin. 1999;49:202-219.
  3. Listing of approved oncology drugs with approved indications. Available at: http://www.fda.gov/cder/cancer/approved.htm. Accessed December 18, 2002.
  4. Advanced Colorectal Cancer Meta-analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol. 1992;10:896-903.
  5. Meta-analysis Group in Cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol. 1998;16:301-308.
  6. de Gramont A, Bossett JF, Milan C, et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French Intergroup study. J Clin Oncol. 1997;15:808-815.
  7. Saltz L, Cox J, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med. 2000;343:905-914.
  8. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a mulitcentre randomized trial. Lancet. 2000;355:1041-1047.
  9. Irinotecan [package insert]. Kalamazoo, Mich: Pharmacia & Upjohn Company; 2002.
  10. Oxaliplatin [package insert]. Malvern, Pa: Sanofi-Synthelabo Inc; 2002.
  11. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000;18:2938-2947.
  12. Goldberg R, Morton D, Sargent C, et al. N9741: oxaliplatin (oxal) or CPT-11 + 5-fluorouracil (5FU)/leucovorin (LV) or oxal + CPT-11 in advanced colorectal cancer (CRC): initial toxicity and response data from a GI Intergroup study [abstract]. Proc Am Soc Clin Oncol. 2002;21:128a. Abstract 511.
  13. Goldberg RM, Morton RF, Sargent DJ, et al. N9741: oxaliplatin (oxal) or CPT-11 + fluorouracil (5FU)/leucovorin (LV) or oxal + CPT-11 in advanced colorectal cancer (CRC). Updated efficacy and quality of life (QOL) data from an intergroup study. Paper presented at: American Society of Clinical Oncology Annual Meeting; June 1, 2003; Chicago, Ill.
  14. Goldberg RM, Morton RF, Sargent DJ, et al. N9741: oxaliplatin (oxal) or CPT-11 + fluorouracil (5FU)/leucovorin (LV) or oxal + CPT-11 in advanced colorectal cancer (CRC). Updated efficacy and quality of life (QOL) data from an intergroup study [abstract]. Proc Am Soc Clin Oncol. 2003;22:252. Abstract 1009.
  15. Tournigand C, Louvet C, Quinaux E, et al. FOLFIRI followed by FOLFOX versus FOLFOX followed by FOLFIRI in metastatic colorectal cancer (MCRC): final results of a phase III study [abstract]. Proc Am Soc Clin Oncol. 2001;20:128a. Abstract 494.
  16. Artru, P, Taieb J, Tournigand CL, et al. FOLFOX7/FOLFIRI (MIROX) regimen as (neo)adjuvant chemotherapy for patients with resectable metastatic colorectal cancer: preliminary results [abstract]. Proc Am Soc Clin Oncol. 2002;21:169a. Abstract 672.
  17. Grothey A, Deschler B, Kroening H, et al. Phase III study of bolus 5-fluorouracil (5-FU)/ folinic acid (FA) (Mayo) vs weekly high-dose 24h 5-FU infusion/ FA + oxaliplatin (OXA) (FUFOX) in advanced colorectal cancer (ACRC) [abstract]. Proc Am Soc Clin Oncol. 2002;21:129a. Abstract 512.
  18. Buechele T, Schoeber, Kroening H, et al. Weekly high-dose (HD) 5-fluorouracil (5-FU) and folinic acid (FA) with addition of oxaliplatin (LOHP) after documented progression under high-dose infusional 5-FU/FA in patients (pts) with advanced colorectal cancer (CRC): a preliminary report [abstract]. Proc Am Soc Clin Oncol. 1998;17:287a. Abstract 1106.
  19. Grothey A, Deschler B, Kroening H, et al. Bolus 5-fluorouracil (5-FU) folinic acid (FA) (Mayo) vs. weekly high-dose 24 h 5-FU infusion/FA + oxaliplatin (OXA) in advanced colorectal cancer (CRC). Results of a phase III study [abstract]. Proc Am Soc Clin Oncol. 2001;20:125a. Abstract 496.
  20. Capecitabine [package insert]. Nutley, NJ: Hoffmann–La Roche, Inc; 2001.
  21. Hoff PM, Ansari R, Batist G, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol. 2001;19:2282-2292.
  22. Hurwitz H, Fehrenbacher L, Cartwright T, et al. Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) prolongs survival in first-line colorectal cancer (CRC): results of a phase III trial of bevacizumab in combination with bolus IFL (irinotecan, 5-fluorouracil, leucovorin) as first-line therapy in subjects with metastatic CRC. Paper presented at: American Society of Clinical Oncology Annual Meeting; June 1, 2003; Chicago, Ill.
  23. Benson AB, Catalano PJ, Meropol NJ, et al. Bevacizumab (anti-VEGF) plus FOLFOX4 in previously treated advanced colorectal cancer (advCRC): an interim toxicity analysis of the Eastern Cooperative Oncology Group (ECOG) study 3200. Proc Am Soc Clin Oncol. 2003;22:243. Abstract 975.

Top of page

New Challenges for Symptom Management in CRC
Gail M. Wilkes, RNC, MS, ANP, AOCN

  1. Irinotecan [package insert]. Kalamazoo, Mich: Pharmacia & Upjohn Company; 2002.
  2. Rothenberg ML, Meropol NJ, Poplin EA, et al. Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J Clin Oncol. 2001;19:3801-3807.
  3. Sweeney C, Seitz D, Ansare R, et al. A phase II trial of irinotecan (I), 5-fluorouracil (F), leucovorin (L) (IFL), celecoxib and glutamine as first line therapy for advanced colorectal cancer: a Hoosier Oncology Group study [abstract]. Proc Am Soc Clin Oncol. 2002;21:105b. Abstract 2235.
  4. Lockich JJ, Ahlgren JD, Gullo JJ, et al. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study. J Clin Oncol. 1989;7:425-432.
  5. Capecitabine [package insert]. Nutley, NJ: Roche Laboratories Inc; 2003.
  6. Doxorubicin HCl liposome injection [package insert]. Bridgewater, NJ: Ortho Biotech; 2002.
  7. Abushullaih S. Incidence and severity of hand-foot syndrome in colorectal cancer patients treated with capecitabine: a single-institution experience. Cancer Invest. 2002;20:3-10.
  8. Yee S, Saffra T, Jeffers S. Prevention and management of Doxil-related side effects: basic strategies [abstract]. Proc Am Soc Clin Oncol. 1998;17:72a. Abstract 281.
  9. Lin EH, Morris J, Chau NK, et al. Celecoxib attenuated capecitabine-induced hand-and-foot syndrome (HFS) and diarrhea and improved time to tumor progression in metastatic colorectal cancer (MCRC) [abstract]. Proc Am Soc Clin Oncol. 2002;21:138b. Abstract 2364.
  10. Hoff PM, LoRusso P, Lokich JJ, et al. Chemotherapy Associated Hand-Foot Syndrome: A Clinician’s Guide to Diagnosis and Management. Nutley, NJ: Roche Pharmaceuticals; 2000.
  11. Longfield V, Hasan E, Romie A. Retrospective evaluation of the use of pyridoxine in the prevention and treatment of palmar-plantar erythrodysesthesia in capecitabine-treated cancer patients. Available at: http://www.ons.org/xp6
    /ONS/Convention.xml/Abstracts.xml/Abstracts_2001_.xml    . Abstract 11.
  12. Hussein MA, Wood L, Saluan MA, et al. Efficacy of pyridoxine to ameliorate cutaneous toxicity associated with Doxil [abstract]. Blood. 1998;92(suppl 1):265b. Abstract 4143.
  13. Kollmannsberger C, Mayer F, Harstrick A, et al. Reduction of skin toxicity of pegylated liposomal doxorubicin by concomitant administration of dexamethasone and pyridoxine in patients with anthracycline-sensitive malignancies: a phase I/II trial. Ann Oncol. 2000;11(suppl 4):136.
  14. Vail DM, Chun R, Thamm DH, et al. Efficacy of pyridoxine to ameliorate the cutaneous toxicity associated with Doxil: a randomized, double-blind clinical trial using a canine model [abstract]. Proc Am Soc Clin Oncol. 1998;17:229a. Abstract 878.
  15. Lopez AM, Wallace L, Dorr RT, et al. Topical DMSO treatment for pegylated liposomal doxorubicin-induced palmar-plantar-erythrodysesthesia. Cancer Chemother Pharmacol. 1999;44:303-306.
  16. Chin SF, Tchen N, Oza AM, et al. Use of “Bag Balm” as topical treatment of palmar-plantar erythrodysesthesia syndrome (PPES) in patients receiving selected chemotherapeutic agents [abstract]. Proc Am Soc Clin Oncol. 2001;20:409a. Abstract 1632.
  17. Oxaliplatin [package insert]. Malvern, Pa: Sanofi-Synthelabo Inc; 2002.
  18. Wilkes GM. New therapeutic options in colon cancer: focus on oxaliplatin. Clin J Oncol. 2001;19:3801-3807.
  19. de Gramont A, Boni C, Navarro M, et al. Oxaliplatin/5-FU/LV in adjuvant colon cancer: safety results of the international randomized MOSAIC trial [abstract]. Proc Am Soc Clin Oncol. 2002;21:132a. Abstract 525.
  20. Maindrault-Goebel F, Louvet C, Andre T, et al. Oxaliplatin reintroduction in patients pretreated with leucovorin, fluorouracil and oxaliplatin for metastatic colorectal cancer (MCRC). Ann Oncol. 2000;11(suppl 4):50.
  21. Andre T, Figer A, Cervantes A, et al. FOLFOX7 compared to FOLFOX4: preliminary results of the randomized optimox study [abstract]. Proc Am Soc Clin Oncol. 2003;22:253. Abstract 1016.
  22. Almadrones LA. Peripheral neuropathies associated with chemotherapy. Advances in Colorectal Cancer Care [newsletter]. Available at: http://www.meniscus.com/advancescrc.
  23. Vahdat L, Papadopoulos K, Lange D, et al. Reduction of paclitaxel-induced peripheral neuropathy with glutamine. Clin Cancer Res. 2001;7:1192-1197.
  24. Gamelin E, Gamelin L, Delva R, et al. Prevention of oxaliplatin peripheral sensory neuropathy by Ca+ gluconate/Mg+ chloride infusions: a retrospective study [abstract]. Proc Am Soc Clin Oncol. 2002;21:157a. Abstract 624.

Top of page

Maximizing the Interface Between Clinic and Home Care
Patricia C. Kiley, RN, BSN

  1. Oxaliplatin [package insert]. Malvern, Pa: Sanofi-Synthelabo Inc; 2002.

Top of page